Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis

Bernardete Pessoa,1,2 Luísa Malheiro,1 Inês Carneiro,1 Sílvia Monteiro,1 João Coelho,1 Constança Coelho,3 João Figueira,4– 6 Angelina Meireles,1,2 João Nuno Melo Beirão1,2 1Ophthalmology Department, Cent...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pessoa B, Malheiro L, Carneiro I, Monteiro S, Coelho J, Coelho C, Figueira J, Meireles A, Melo Beirão JN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	aflibercept bevacizumab diabetic macular edema ranibizumab refractory Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/49d4ee1103c2406183bd4505af1fe08e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49d4ee1103c2406183bd4505af1fe08e
record_format	dspace
spelling	oai:doaj.org-article:49d4ee1103c2406183bd4505af1fe08e2021-12-02T15:24:15ZIntravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis1177-5483https://doaj.org/article/49d4ee1103c2406183bd4505af1fe08e2021-01-01T00:00:00Zhttps://www.dovepress.com/intravitreal-ranibizumab-or-aflibercept-after-bevacizumab-in-diabetic--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Bernardete Pessoa,1,2 Luísa Malheiro,1 Inês Carneiro,1 Sílvia Monteiro,1 João Coelho,1 Constança Coelho,3 João Figueira,4– 6 Angelina Meireles,1,2 João Nuno Melo Beirão1,2 1Ophthalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; 3Genetics Laboratory, Institute of Environmental Health, Lisbon Medical School, University of Lisbon, Porto, Portugal; 4Centro Hospitalar e Universitário de Coimbra, Porto, Portugal; 5Faculty of Medicine of the University of Coimbra, Porto Portugal; 6Association for Innovation and Biomedical Research on Light and Image, Coimbra, PortugalCorrespondence: Bernardete PessoaCentro Hospitalar e Universitário do Porto – Hospital de Santo António, Departamento de Oftalmologia, Largo Prof. Abel Salazar, Edifício Neoclássico, Porto 4099-001, PortugalTel +351 938469884Email bbtpessoa@gmail.comAim: To evaluate the efﬁcacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed.Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p< 0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p< 0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept.Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. Clinicaltrials.gov NCT04018833.Keywords: aflibercept, bevacizumab, diabetic macular edema, ranibizumab, refractoryPessoa BMalheiro LCarneiro IMonteiro SCoelho JCoelho CFigueira JMeireles AMelo Beirão JNDove Medical Pressarticleafliberceptbevacizumabdiabetic macular edemaranibizumabrefractoryOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 253-260 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	aflibercept bevacizumab diabetic macular edema ranibizumab refractory Ophthalmology RE1-994
spellingShingle	aflibercept bevacizumab diabetic macular edema ranibizumab refractory Ophthalmology RE1-994 Pessoa B Malheiro L Carneiro I Monteiro S Coelho J Coelho C Figueira J Meireles A Melo Beirão JN Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
description	Bernardete Pessoa,1,2 Luísa Malheiro,1 Inês Carneiro,1 Sílvia Monteiro,1 João Coelho,1 Constança Coelho,3 João Figueira,4– 6 Angelina Meireles,1,2 João Nuno Melo Beirão1,2 1Ophthalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal; 3Genetics Laboratory, Institute of Environmental Health, Lisbon Medical School, University of Lisbon, Porto, Portugal; 4Centro Hospitalar e Universitário de Coimbra, Porto, Portugal; 5Faculty of Medicine of the University of Coimbra, Porto Portugal; 6Association for Innovation and Biomedical Research on Light and Image, Coimbra, PortugalCorrespondence: Bernardete PessoaCentro Hospitalar e Universitário do Porto – Hospital de Santo António, Departamento de Oftalmologia, Largo Prof. Abel Salazar, Edifício Neoclássico, Porto 4099-001, PortugalTel +351 938469884Email bbtpessoa@gmail.comAim: To evaluate the efﬁcacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab.Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed.Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p< 0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p< 0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept.Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. Clinicaltrials.gov NCT04018833.Keywords: aflibercept, bevacizumab, diabetic macular edema, ranibizumab, refractory
format	article
author	Pessoa B Malheiro L Carneiro I Monteiro S Coelho J Coelho C Figueira J Meireles A Melo Beirão JN
author_facet	Pessoa B Malheiro L Carneiro I Monteiro S Coelho J Coelho C Figueira J Meireles A Melo Beirão JN
author_sort	Pessoa B
title	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
title_short	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
title_full	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
title_fullStr	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
title_full_unstemmed	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
title_sort	intravitreal ranibizumab or aflibercept after bevacizumab in diabetic macular edema: exploratory retrospective analysis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/49d4ee1103c2406183bd4505af1fe08e
work_keys_str_mv	AT pessoab intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT malheirol intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT carneiroi intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT monteiros intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT coelhoj intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT coelhoc intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT figueiraj intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT meirelesa intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis AT melobeiraojn intravitrealranibizumaborafliberceptafterbevacizumabindiabeticmacularedemaexploratoryretrospectiveanalysis
_version_	1718387261910810624

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis

Ejemplares similares